Journal article
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
Abstract
BACKGROUND: Controversy persists about whether chemotherapy benefits all breast cancer patients.
PATIENTS AND METHODS: In the International Breast Cancer Study Group (IBCSG) trial VII, 1212 postmenopausal patients with node-positive disease were randomized to receive tamoxifen for 5 years or tamoxifen plus three concurrent courses of cyclophosphamide, methotrexate and 5-fluorouracil ('classical' CMF) chemotherapy, either early, delayed or both. …
Authors
Colleoni M; Li S; Gelber RD; Coates AS; Castiglione-Gertsch M; Price KN; Lindtner J; Rudenstam C-M; Crivellari D; Collins J
Journal
Annals of Oncology, Vol. 16, No. 5, pp. 716–725
Publisher
Elsevier
Publication Date
May 2005
DOI
10.1093/annonc/mdi163
ISSN
0923-7534
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsConfidence IntervalsCyclophosphamideDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFluorouracilHumansMastectomy, SegmentalMethotrexateMiddle AgedNeoplasms, Hormone-DependentPostmenopauseProbabilityPrognosisReference ValuesRisk AssessmentSurvival RateTamoxifenTime FactorsTreatment Outcome